{"eventGroups":[{"description":"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.\n\nGVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0.\n\nanti-thymocyte globulin : Given IV\n\npharmacological study : Correlative studies\n\nfludarabine phosphate : Given IV\n\nbusulfan : Given IV\n\nbortezomib : Given IV\n\nallogeneic hematopoietic stem cell transplantation : Undergo allogeneic HSCT\n\ntacrolimus : Given IV\n\nlaboratory biomarker analysis : Correlative studies\n\nsirolimus : Given PO","id":"EG000","otherNumAffected":0,"otherNumAtRisk":1,"seriousNumAffected":1,"seriousNumAtRisk":1,"title":"Treatment (Chemotherapy, Enzyme Inhibitor)"}],"frequencyThreshold":"5","seriousEvents":[{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Mucositis oral"},{"organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":2}],"term":"Fever"},{"organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Staphylococcus bacteremia"},{"organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"CMV"},{"organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1,"numEvents":1}],"term":"Headache"}]}